FDA Electronic Records and Electronic Signatures
Ensuring integrity and authenticity of electronic records in FDA-regulated industries
// What is FDA 21 CFR Part 11?
21 CFR Part 11 establishes FDA requirements for electronic records and electronic signatures to be considered trustworthy, reliable, and equivalent to paper records and handwritten signatures. The regulation applies to any records required by FDA predicate rules that are created, modified, maintained, or transmitted in electronic form.
Part 11 addresses three key areas: ensuring electronic records are accurate and unaltered, establishing that electronic signatures are legally binding, and requiring audit trails that capture who did what and when. Organizations must implement technical controls, procedural safeguards, and administrative policies to maintain compliance.
The regulation is critical for pharmaceutical manufacturers, medical device companies, biotech firms, clinical research organizations, and any entity subject to FDA oversight that uses electronic systems for regulated activities.
// Inside the Regulation
Part 11 is organized into three subparts covering general provisions, electronic records requirements, and electronic signature requirements. Compliance requires a combination of technical controls and procedural measures.
Subpart A: General Provisions
Defines scope, applicability, and key definitions for electronic records and signatures.
Scope
Applies to electronic records created, modified, maintained, archived, retrieved, or transmitted under FDA regulations.
Predicate Rules
Part 11 applies when underlying FDA regulations (predicate rules) require records to be maintained or submitted.
Risk-Based Approach
FDA guidance encourages risk-based implementation, focusing controls on records critical to product quality and safety.
Subpart B: Electronic Records
Technical and procedural controls required for electronic records to be trustworthy and reliable.
Audit Trails
Computer-generated, time-stamped audit trails recording operator entries and actions. Trails must be retained and available for FDA review.
System Access Controls
Limiting system access to authorized individuals through unique user IDs, passwords, and role-based permissions.
Authority Checks
Ensuring users can only perform functions they are authorized to perform within the system.
Device Checks
Validation that data input sources (instruments, devices) are functioning correctly.
Operational System Checks
Enforcement of permitted sequencing of events and proper data entry.
Subpart C: Electronic Signatures
Requirements for electronic signatures to be legally equivalent to handwritten signatures.
Signature Uniqueness
Electronic signatures must be unique to one individual and not reused or reassigned.
Identity Verification
Organizations must verify identity before assigning electronic signature credentials.
Signature Components
Biometric or non-biometric signatures with at least two distinct identification components (e.g., user ID + password).
Signature Manifestation
Signed records must display the printed name, date/time, and meaning of the signature (e.g., approval, review).
Note: FDA's 2003 guidance on Part 11 clarified a risk-based approach to implementation. The agency focuses enforcement on records that are critical to product quality and patient safety. Organizations should validate computerized systems per GAMP guidelines and maintain validation documentation.
// Who Must Comply
- 1 Pharmaceutical manufacturers and distributors
- 2 Medical device manufacturers
- 3 Biotechnology and biologics companies
- 4 Clinical research organizations (CROs) and clinical trial sponsors
- 5 Contract manufacturing organizations (CMOs)
- 6 Laboratories performing FDA-regulated testing
- 7 Food manufacturers subject to FDA oversight
// Key Requirements
Audit Trails
Secure, computer-generated audit trails tracking all record changes with timestamps and user identification
Access Controls
System controls ensuring only authorized individuals can access, create, or modify records
Electronic Signatures
Unique, verified electronic signatures with at least two identification components
System Validation
Documented validation ensuring systems perform as intended and maintain data integrity
Documentation
Written policies and procedures for system use, security, and electronic signature practices
Training
Personnel training on GMP/GLP requirements, system operation, and electronic signature responsibilities
// Enforcement & Penalties
Part 11 violations can result in FDA warning letters, consent decrees, product seizures, and import alerts. Non-compliant electronic records may be rejected by FDA, potentially invalidating clinical trial data or manufacturing batch records.
Warning letters, consent decrees, product seizures, criminal prosecution
Examples:
- FDA warning letters citing Part 11 deficiencies
- 483 observations during facility inspections
- Rejection of electronic submissions and data
- Consent decrees requiring extensive remediation
- Product recalls due to data integrity failures
- Import alerts blocking product entry to U.S. market
// Cyber Insurance Impact
Life sciences companies with strong Part 11 compliance programs may receive more favorable product liability and cyber insurance terms. Data integrity failures can trigger costly recalls and litigation, making compliance a risk management priority for insurers.
// How Breach Craft Helps
We help organizations achieve FDA 21 CFR Part 11 compliance through genuine security improvements—not checkbox exercises. Our services address the specific requirements and challenges of FDA 21 CFR Part 11.
Ready to Strengthen Your Defenses?
Schedule a free consultation with our security experts to discuss your organization's needs.
Or call us directly at (445) 273-2873